© DEC 2025 | IRE Journals | Volume 9 Issue 6 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I6-1712583

ALZMIND: Machine Learning- Powered Early Diagnosis and Accurate Testing of Alzheimer's Disease

ZOYA MUSKAAN[1], VIDYAVATHI G K[2], SYED NIZAMUDDIN QUADRI[3], TASMIA NIDA[4]
[1,2,3,4] *Dept. of Computer Science and Eng., Ghousia College of Engineering Ramanagara, India*

Abstract*— Alzheimer's disease (AD) is a chronic neurodegenerative disorder that progressively deteriorates memory, cognition, and behavioral stability. The absence of reliable early diagnostic mechanisms often results in delayed detection and treatment inefficiency. This paper presents ALZMIND, a machine learning-driven digital health platform developed to facilitate early diagnosis and precise cognitive testing for Alzheimer's disease. The system architecture comprises four integrated components: (i) user registration, authentication, and informed consent management; (ii) role-specific dashboards enabling researchers and patients to monitor and visualize cognitive performance; (iii) a clinical trial matching module that leverages user data and eligibility criteria to recommend relevant ongoing studies; and (iv) a cognitive assessment module employing an interactive memory game and quiz to evaluate recall accuracy, attention span, and recognition ability. The data obtained are analyzed using supervised learning algorithms to detect deviations indicative of early cognitive decline. By combining predictive analytics with user interaction data, ALZMIND aims to enhance diagnostic precision, accelerate research participation, and contribute to early intervention strategies. Experimental results and system evaluation demonstrate the feasibility of integrating artificial intelligence within clinical workflows for neurodegenerative disease management.

Keywords*— Alzheimer's Disease, Machine Learning, Cognitive Assessment, Early Diagnosis, Clinical Trial Matching, Predictive Analytics, Digital Health, Neurodegenerative Disorders

I. INTRODUCTION

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders, primarily affecting the elderly population. It gradually impairs memory, reasoning, and behavior, ultimately disrupting an individual's ability to perform daily activities. According to the World Health Organization, the number of people living with dementia is expected to rise sharply in the coming decades, with Alzheimer's accounting for nearly 60–70% of all dementia cases. expected to rise sharply in the coming decades, with Alzheimer's accounting for nearly 60–70% of all dementia cases. Despite significant progress in neuroscience and datadriven medicine, early detection of Alzheimer's remains a major clinical challenge. Conventional diagnostic methods, such as neuroimaging and biomarker analysis, are expensive, invasive, and often inaccessible to many individuals at risk.

Recent advancements in machine learning (ML) and digital health technologies have opened new pathways for developing intelligent diagnostic systems capable of detecting subtle cognitive changes at earlier stages. ML models can analyze behavioral patterns, cognitive test results, and clinical data to identify early indicators of mental decline with higher accuracy than traditional screening techniques. These technologies not only enhance diagnostic precision but also support researchers in understanding disease progression and evaluating treatment outcomes.

The proposed system, ALZMIND, is a machine learningpowered platform designed to simplify early Alzheimer's diagnosis and improve accessibility to cognitive testing and clinical research. The platform integrates user registration, secure authentication, and informed consent to ensure ethical participation. It features two dashboards—one for patients and another for researchers—to enable data-driven interaction and visualization. Additionally, ALZMIND incorporates a cognitive testing module, consisting of a memory-based quiz or game that helps evaluate a user's attention, recall, and pattern recognition ability. A clinical trial matching feature further assists in connecting eligible patients with ongoing studies, promoting collaboration between research and patient communities.

By combining predictive analytics with interactive cognitive evaluation, ALZMIND aims to provide an affordable, user-friendly, and efficient tool for early detection of Alzheimer's disease. The system not only facilitates clinical decision-making but also contributes to advancing precision healthcare and research in neurodegenerative disorders.

© DEC 2025 | IRE Journals | Volume 9 Issue 6 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I6-1712583

II. LITERATURE REVIEW

Over the past decade, numerous studies have explored the use of computational intelligence for the early diagnosis and prognosis of Alzheimer's disease (AD). Traditional diagnostic techniques rely on neuropsychological assessments and neuroimaging, yet these approaches are often limited by cost, availability, and subjectivity in interpretation. As a result, researchers have increasingly adopted machine learning (ML) and deep learning (DL) methodologies to enhance diagnostic accuracy and identify biomarkers associated with cognitive decline.

Tong et al. (2017) proposed a novel grading biomarker for predicting the conversion from mild cognitive impairment (MCI) to AD using magnetic resonance imaging (MRI) features. Their study emphasized the importance of feature selection, age correction, and sparse representation techniques in improving classification accuracy. Using the ADNI dataset, they achieved an area under the ROC curve (AUC) of up to 92%, demonstrating that combining imaging biomarkers with cognitive measures significantly enhances prediction reliability.

Mahyoub et al. (2018) conducted a comparative analysis of ML algorithms to rank Alzheimer's disease risk factors by importance Their research highlighted the role of behavioral and biological markers, including genetic predisposition, family dementia history, education level, and lifestyle factors. By deploying supervised ML models such as Random Forests, Neural Networks, and Support Vector Machines, they identified APOE4, education, and age as the most influential features in AD progression. The study reinforced the need for data-driven methods capable of integrating multidimensional clinical datasets for risk assessment.

Deep learning approaches have also shown remarkable promise in recent years. Vinutha et al. (2024) developed a Convolutional Neural Network (CNN)-based classifier for AD diagnosis using structural MRI images.Their framework processed longitudinal and cross-sectional neuroimages from the ADNI dataset and achieved robust classification performance, illustrating that CNNs can effectively extract latent spatial features without manual feature engineering. Similar efforts by Vimaladevi et al. (2024) investigated handwriting dynamics as a non-invasive diagnostic tool.By analyzing pen pressure, stroke velocity, and spatial-temporal patterns, their model distinguished AD patients from healthy individuals with over 90% accuracy using Random Forest and Support Vector Classifiers. These studies demonstrate the growing value of behavioral and kinematic biomarkers as accessible indicators of cognitive impairment.

Parallel advancements in pervasive and assistive computing technologies have further expanded the landscape of Alzheimer's care. Tung et al. (2013) discussed the Everyday Technologies for Alzheimer's Care (ETAC) initiative, which leverages pervasive computing and mobile systems for continuous cognitive monitoring and home-based assessment. Their research emphasized that early detection through digital interfaces can significantly enhance patient independence, safety, and quality of life. Similar efforts in smart home environments and mobile health systems have proven beneficial for monitoring cognitive decline, enabling real-time intervention, and supporting caregivers.

Collectively, these studies highlight the growing convergence of machine learning, behavioral analytics, and digital health technologies in Alzheimer's research. While imaging-based models provide high diagnostic accuracy, they often require specialized equipment and clinical expertise. Conversely, behavioral and digital biomarkers offer scalable and cost-effective alternatives suitable for large populations. The ALZMIND framework builds upon these findings by integrating cognitive testing, clinical trial matching, and realtime analytics into a unified, user-friendly platform. By merging AI-driven insights with digital cognitive assessments, ALZMIND aims to deliver an accessible and ethically grounded tool for early-stage Alzheimer's detection and research collaboration.

III. PROPOSED METHODOLOGY

The proposed system, ALZMIND, is developed as a webbased intelligent platform that integrates machine learning, deep learning, and Flask-based web technologies to enable early diagnosis and monitoring of Alzheimer's disease. The overall framework focuses on four major goals: (i) efficient user management and ethical consent handling, (ii) interactive cognitive testing and prediction, (iii) secure data storage and visualization, and (iv) automated clinical trial matching and reporting.

3.1 System Architecture:
The ALZMIND system follows a client–server architecture where the frontend handles user interaction and visualization, while the backend performs data processing, prediction, and database operations. The application is built using Flask (v3.1.2) as the main web framework due to its lightweight and modular nature. Flask's integration with Flask_SQLAlchemy, Flask_Login, and Flask_Bcrypt ensures secure user authentication, encrypted password management, and robust database handling.The backend server is developed in Python, which supports seamless interaction between the web interface and the machine learning modules. All sensitive data are stored using SQLAlchemy ORM with database migration capabilities handled by Flask_Migrate. Flask_CORS is implemented to enable cross-platform communication between the backend and any future mobile or cloud components.

3.2 Machine Learning and Deep Learning Integration:
The analytical backbone of ALZMIND relies on a combination of traditional machine learning and deep learning approaches. For structured cognitive data (quiz responses, accuracy, and time-based metrics), a Random Forest Classifier from scikit-learn is implemented to predict cognitive impairment levels. This model was selected for its interpretability, high accuracy, and resilience to overfitting.In addition, the system is designed to accommodate a deep learning module built using PyTorch and torchvision, intended for analyzing visual biomarkers such as MRI scans. This module applies Convolutional Neural Network (CNN) architectures for image-based feature extraction and classification. By combining classical ML with deep neural networks, the platform achieves both structured and unstructured data analysis capabilities—bridging clinical and behavioral diagnostics.Data preprocessing and transformation are supported by NumPy and SciPy, ensuring consistent numerical operations. Model training and evaluation employ standard metrics such as accuracy, precision, recall, and F1score to assess diagnostic performance.

3.3 Cognitive Testing and Prediction Module:
A key feature of ALZMIND is its interactive cognitive test, designed as a web-based quiz or memory game that evaluates attention, recall, and decision-making. The responses collected—such as score, reaction time, and error rate—are converted into numerical features for analysis.The RandomForestClassifier model predicts the likelihood of early cognitive decline based on these parameters. The results are visualized on the patient dashboard, allowing users to monitor their cognitive trends over time. The predictions are stored securely and made available to researchers in anonymized form to aid further analysis.

3.4 User Management and Ethical Consent:
Every participant—whether a patient or a researcher— must register through a secure Flask_Login interface. During registration, an informed consent form is digitally presented, ensuring ethical compliance and user awareness regarding data Offers aggregated and anonymized datasets for trend analysis, model evaluation, and user management. Researchers can monitor participant engagement and study outcomes securely. The dashboards are implemented using Flask's Jinja2 templating engine, providing a responsive and data-driven interface for real-time insights.

3.5 Dashboard and Visualization:
Two interactive dashboards are provided:Patient Dashboard: Displays cognitive test performance, visual analytics (using ReportLab and Matplotlib), and clinical trial recommendations. Users can download PDF summaries of their results for personal or clinical use.Researcher Dashboard: and non-technical users while maintaining professional documentation standards.

3.6 Clinical Trial Matching and Reporting:
The clinical trial matching module uses user attributes (age, diagnosis category, cognitive score) to recommend appropriate research studies. This feature acts as a bridge between patients and the research community, facilitating faster recruitment and improving the quality of clinical data.Automated report generation is implemented through ReportLab, enabling PDF summaries of diagnostic results and recommendations. This ensures accessibility for both clinical usage. Passwords are encrypted using Flask_Bcrypt, and all communication between the client and server is handled securely.The Flask_SQLAlchemy ORM maintains structured storage of user data, while Alembic handles version control for database migrations. This ensures

© DEC 2025 | IRE Journals | Volume 9 Issue 6 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I6-1712583

reliability, consistency, and scalability in managing sensitive medical information.

3.7 Workflow Summary:

The overall workflow of ALZMIND can be summarized as follows:

User Interaction: Patients and researchers register, authenticate, and provide consent.

Cognitive Data Collection: Users complete a memory based cognitive test.

Feature Extraction: The system processes responses and prepares numerical input data.

Prediction: ML/DL models classify the user's cognitive state.

Result Visualization: Personalized outcomes and recommendations are displayed on dashboards.

Reporting and Research: Data is anonymized, analyzed, and made available for ongoing studies.



3.8 Security and Privacy:

Given the sensitivity of medical data, the system employs password hashing, encrypted storage, and secure APIs for all transactions. Personal identifiers are separated from cognitive data to preserve anonymity. Flask's built-in security mechanisms combined with CORS and ORM-level validation ensure data integrity and ethical compliance throughout the system.

3.9 Summary:

The ALZMIND platform integrates multiple technologies—Flask, scikit-learn, PyTorch, SQLAlchemy, and ReportLab—into a unified, intelligent framework for early Alzheimer's detection. By combining cognitive testing, predictive analytics, and clinical trial matching, it provides an end-to-end digital health solution that promotes accessibility, research collaboration, and early intervention for neurodegenerative disorders.

IV. RESULTS AND DISCUSSION

The ALZMIND system was successfully developed and deployed as a modular Flask-based web platform integrating machine learning and deep learning components for Alzheimer's prediction and research assistance. Each subsystem—user authentication, cognitive testing, model inference, data visualization, and clinical trial matching— was independently tested and validated for performance, usability, and accuracy.



4.1 Functional Evaluation:

The platform was hosted locally during testing, with user interactions simulated through the Flask web interface. The user registration and login modules performed reliably, ensuring secure access through encrypted authentication managed by Flask_Bcrypt. The consent management feature worked as intended, capturing informed consent before participation.The cognitive testing module delivered a smooth and

© DEC 2025 | IRE Journals | Volume 9 Issue 6 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I6-1712583

interactive experience. Users completed a short-term memory quiz where their accuracy, response time, and error rates were recorded. The data pipeline—built using NumPy and SciPy—efficiently processed these inputs and passed them to the trained Random Forest Classifier for prediction.Overall system latency from data submission to prediction output averaged 1.2 seconds, demonstrating realtime responsiveness suitable for online health assessment platforms. The dashboards, implemented using Flask templates and visualized via ReportLab, effectively displayed personalized cognitive scores and generated downloadable reports for patients and researchers.

4.2 Machine Learning Model Performance:
The machine learning model was trained using a structured dataset containing cognitive test parameters labeled as Normal, Mild Cognitive Impairment (MCI), and Possible Alzheimer's. After hyperparameter tuning and five-fold crossvalidation, the Random Forest Classifier achieved an overall accuracy of 91.6%, with precision = 90.4%, recall = 92.1%, and an F1-score of 91.2%.The confusion matrix revealed that the model classified "Normal" and "MCI" cases with high reliability, while a few "Possible Alzheimer's" instances were misclassified due to overlapping cognitive patterns—a common challenge in behavioral data modeling.In parallel, the deep learning component developed using PyTorch and torchvision was tested on a limited MRI dataset for proof of concept. The Convolutional Neural Network (CNN) achieved a preliminary accuracy of 88.3%, confirming its potential for integration in future system upgrades involving multimodal data inputs.These results validate the hybrid approach—combining behavioral quiz-based data with image-based analysis—as a strong framework for Alzheimer's screening and progression monitoring.

4.3 Usability and User Testing:
To evaluate usability, a small group of 20 volunteer participants, including students and healthcare trainees, were asked to interact with the platform. The System Usability Score (SUS) averaged 86.5, indicating excellent user experience and interface clarity.Participants appreciated the simplicity of navigation, the visual feedback of test results, and the secure registration process. Most users found the memory quiz engaging and non-stressful compared to traditional diagnostic questionnaires. Minor feedback included suggestions for longer test durations and gamified interaction for better engagement.Researchers reviewing the system commended the clinical trial matching feature, noting its potential to accelerate participant recruitment and streamline communication between research centers and potential subjects.

4.4 Comparative Analysis:
When compared to similar machine learning-based Alzheimer's systems reported in prior studies, ALZMIND demonstrated comparable or improved prediction accuracy while offering enhanced accessibility through a web-based interface. Existing approaches often rely solely on neuroimaging or clinical biomarkers, which are resourceintensive and inaccessible for early population-level screening.In contrast, ALZMIND's quiz-based cognitive evaluation requires no specialized hardware, enabling broader reach, especially in non-clinical settings such as community health centers or early screening programs. The integration of both machine learning and deep learning elements gives the system a flexible structure for future expansion toward multimodal diagnosis.



4.5 Ethical and Security Evaluation:
The system ensures data privacy through password hashing, encrypted databases, and consent-based participation. All patient identifiers are anonymized before analysis, ensuring compliance with ethical standards for digital health systems. These security measures make ALZMIND reliable for real-world clinical environments, where data integrity and privacy are paramount.

4.6 Discussion:
The experimental outcomes confirm that ALZMIND is capable of providing early cognitive evaluation and predictive diagnosis in a lightweight, accessible web environment. The strong classification metrics of the Random Forest model, coupled with the system's high usability, demonstrate that such platforms can

effectively bridge the gap between AI-driven research and real-world healthcare delivery.Compared to imaging-only systems, ALZMIND lowers diagnostic costs while maintaining meaningful accuracy. Its modular design ensures scalability for future integration with IoT devices, speech analytics, or EEG data. Moreover, the inclusion of clinical trial matching aligns the system with research ethics and long-term patient engagement strategies.

4.7 Summary:

In conclusion, the ALZMIND system achieved promising results across both technical and usability evaluations. It demonstrated accurate machine learning– based prediction of cognitive decline, user-friendly dashboards, and secure handling of sensitive data. These findings indicate the feasibility of deploying such AI-driven systems for community-level Alzheimer's screening and research support, paving the way for more inclusive and technology-assisted cognitive healthcare.

V. CONCLUSION AND FUTURE WORK

This research presented ALZMIND, a machine learning– powered digital health platform designed for the early diagnosis and accurate testing of Alzheimer's disease. The system integrates Flask-based web technologies, machine learning, and deep learning frameworks to deliver a unified solution that supports patients, caregivers, and researchers. By combining cognitive quiz–based assessments with intelligent classification models, ALZMIND enables early identification of cognitive decline in a simple, accessible, and cost-effective manner.Experimental results demonstrated that the Random Forest Classifier achieved over 91% accuracy in classifying cognitive states, while the deep learning prototype using PyTorch achieved promising results for MRI-based analysis. The platform's usability evaluation showed strong user satisfaction, validating its practicality and effectiveness in real-world scenarios. Its built-in clinical trial matching feature further strengthens collaboration between patients and research communities.In the future, the system can be expanded to include larger clinical datasets, speech and handwriting-based biomarkers, and deep learning architectures such as CNN–LSTM hybrids for temporal cognitive analysis. Integration with IoT and wearable devices could also enable continuous real-time monitoring. Overall, ALZMIND demonstrates the potential of AI-driven digital health solutions to transform early Alzheimer's diagnosis and contribute to the broader field of precision healthcare.

VI. ACKNOWLEDGMENT

We would like to express their sincere gratitude to our project supervisor and faculty of the Department of Computer Science and Engineering for their constant guidance, valuable suggestions, and encouragement throughout the development of this project.Finally, we extend our appreciation to all participants and contributors whose feedback helped us refine and improve the ALZMIND system. The patience and support received from our families cannot be neglected. Finally we can say alhamdulillah and blessings be on all of his all prophet especially the last one.

REFERENCES

[1] Tong, T., Gray, K., Gao, Q., Chen, L., Rueckert, D., "Multi-Modal Classification of Alzheimer's Disease Using Novel Grading Biomarker," Medical Image Computing and Computer-Assisted Intervention (MICCAI), vol. 10433, pp. 338–346, 2017.

[2] Mahyoub, F., Amoon, M., & Ahmed, A., "Ranking of Alzheimer's Disease Risk Factors Using Machine Learning Algorithms," International Journal of Advanced Computer Science and Applications (IJACSA), vol. 9, no. 5, pp. 212–219, 2018.

[3] Vinutha, K. S., et al., "Prediction of Alzheimer's Disease Using Convolutional Neural Network (CNN) on MRI Images," IEEE International Conference on Computational Intelligence and Data Science (ICCIDS), 2024.

[4] Vimaladevi, S., Anandaraj, J., & Priya, M., "Detection of Alzheimer's Disease Using Handwriting Dynamics and Machine Learning Techniques," Journal of Computational and Cognitive Neuroscience, vol. 6, no. 2, 2024.

[5] Tung, J. Y., et al., "Everyday Technologies for Alzheimer's Care (ETAC): Pervasive Computing for Cognition Assessment," Proceedings of the IEEE Pervasive Health Conference, pp. 1–8, 2013.

[6] World Health Organization (WHO), Dementia Fact Sheet, 2023. [Online]. Available: https://www.who.int/news-room/factsheets/detail/dementia.

[7] Alzheimer's Disease International (ADI), World[6] Alzheimer Report 2023: Reducing Dementia Risk, London, U.K., 2023.
[8] Scikit-learn Developers, "Random Forest Classifier Documentation," Scikit-learn: Machine Learning in Python,[Online].Available:https://scikitlearn.org/stable/mod ules/generated/sklearn.ensemble.RandomForestClas sifier.html
[9] Grinberg, M., Flask Web Development: Developing Web Applications with Python, 2nd ed., O'Reilly Media, 2018.
[10] SQLAlchemy Documentation, "Object Relational Mapper (ORM) Guide," [Online]. Available: https://docs.sqlalchemy.org.
[11] ReportLab Developers, "ReportLab User Guide," ReportLab Toolkit, Version 3.6, 2024. [Online]. Available: https://www.reportlab.com/documentation.
[12] Pedregosa, F., et al., "Scikit-learn: Machine Learning in Python," Journal of Machine Learning Research, vol. 12, pp. 2825–2830, 2011.
[13] United States Department of Health & Human Services (HHS), "HIPAA Privacy Rule Summary," 2023. [Online]. Available: https://www.hhs.gov/hipaa.
[14] Nielsen, J., "Usability Engineering," Morgan Kaufmann Publishers, 1993.
[15] Sauro, J., and Lewis, J. R., "Quantifying the User Experience: Practical Statistics for User Research," Elsevier/Morgan Kaufmann, 2016.
[16] GitHub, "Flask-Bcrypt, Flask-Login, Flask-Migrate, Flask-CORS: Official Documentation," [Online]. Available: https://flask.palletsprojects.com.
[17] NumPy Developers, "NumPy User Guide," [Online]. Available: https://numpy.org/doc/